Clinical Trials: Studies Seeking Participants
| Famotidine for the treatment of levodopa-induced dyskinesia: An “N-of-1” Study New Clinical Trial: A Famotidine study is seeking participants who meet the following criteria: Men and women diagnosed with Parkinson’s disease who are under 80 years of age, those with a stable Parkinson drug routine for at least one month prior to enrollment in the study and those who experience dyskinesias which are bothersome or challenging in their daily lives. More information Investigational drug in Idiopathic Parkinson’s Disease (IPD) With Cognitive Impairment, as Add-on to Dopamine Agonist and/or Levodopa (COGNITION) This is a clinical trial to see whether an investigational drug1 may be beneficial in treating a non-motor symptom of Parkinson’s (e.g., cognitive changes). The objective of this trial is to evaluate whether the investigational drug, when taken with stable doses of dopamine agonist and/or levodopa, improves cognition in people living with Parkinson’s. More information Disclosure of Parkinson’s disease diagnosis within the workplace, Phase II The purpose of this study is to expand on previous research (Phase I) conducted in January 2011 in central Ontario which investigated workplace disclosure choices (disclosure versus non-disclosure, timing of disclosure events, and reasons for disclosure decisions) among employed people living with Parkinson’s. More information A study to investigate the efficacy, safety and tolerability of CoganeTM (PYM50028) in early stage Parkinson's disease. This is a Phase II, randomized, double-blind, placebo-controlled study testing the effectiveness, safety and tolerability of the new compound. The study is seeking men and women between the age of 35 and 75 years who have been diagnosed with Parkinson's within the last 2 years. Participants should not be taking any medication to manage their Parkinson's symptoms. They should be in good general health and willing to meet the scheduled visits in the study. More information Investigating the D3 Dopamine receptor and its relevance to treatment-induced complications in Parkinson's disease. The goal of this study is to understand how long-term treatment with medication for Parkinson's may lead to adverse side-effects. The study is seeking men and women over the age of 40 years who have Parkinson's disease and are taking levodopa (Sinemet, or generic). Individuals in the Greater Toronto Area and surrounding communities may participate. Participants should be medically fit, be able to understand/follow instructions, not receive treatment for any psychiatric disorder, have no history of alcohol or drug abuse, have no significant head injury, and have no metal implants More information See also: First Person: Choosing a career in neuroscience and Parkinson's (April 2011 issue of e-ParkinsonPost) |
